Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
44
TBPH Quote, Financials, Valuation and Earnings
Last price:
$18.71
Seasonality move
:
7.18%
Day range:
$18.59 - $19.11
52-week range:
$7.90 - $20.33
Dividend yield:
0%
P/E ratio:
33.24x
P/S ratio:
11.74x
P/B ratio:
4.07x
Volume:
331.2K
Avg. volume:
524.3K
1-year change:
94.99%
Market cap:
$947.6M
Revenue:
$64.4M
EPS (TTM):
$0.56
Analysts' Opinion
-
Consensus RatingTheravance Biopharma, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $26.71, Theravance Biopharma, Inc. has an estimated upside of 42.86% from its current price of $18.70.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $13.00 representing 30.48% downside risk from its current price of $18.70.
Fair Value
-
According to the consensus of 7 analysts, Theravance Biopharma, Inc. has 42.86% upside to fair value with a price target of $26.71 per share.
TBPH vs. S&P 500
-
Over the past 5 trading days, Theravance Biopharma, Inc. has underperformed the S&P 500 by -6.42% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Theravance Biopharma, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Theravance Biopharma, Inc. has grown year-over-year revenues for 10 quarters straight. In the most recent quarter Theravance Biopharma, Inc. reported revenues of $20M.
Earnings Growth
-
Theravance Biopharma, Inc. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Theravance Biopharma, Inc. reported earnings per share of $0.07.
Enterprise value:
662.5M
EV / Invested capital:
2.39x
Price / LTM sales:
11.74x
EV / EBIT:
--
EV / Revenue:
8.25x
PEG ratio (5yr expected):
-0.26x
EV / Free cash flow:
2.72x
Price / Operating cash flow:
3.87x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$74.8M
Return On Assets:
7.74%
Net Income Margin (TTM):
36.53%
Return On Equity:
14.9%
Return On Invested Capital:
11.74%
Operating Margin:
-32.29%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $54.5M | $63.2M | $80.3M | $16.9M | $20M | |
| Gross Profit | $48.9M | $56.8M | $74.8M | $15.3M | $18.6M | |
| Operating Income | -$64.5M | -$39.5M | -$32.8M | -$9.3M | -$6.5M | |
| EBITDA | -$58.9M | -$33.1M | -$27.3M | -$7.7M | -$5M | |
| Diluted EPS | -$0.95 | -$1.01 | $0.56 | -$0.26 | $0.07 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $297.2M | $511.7M | $161.7M | $116.5M | $354.7M | |
| Total Assets | $403.1M | $763.5M | $413.6M | $356.1M | $415.5M | |
| Current Liabilities | $66.1M | $142.1M | $25.4M | $23.4M | $37.4M | |
| Total Liabilities | $726.7M | $282.9M | $167.5M | $170.5M | $182.8M | |
| Total Equity | -$323.6M | $480.6M | $246.1M | $185.7M | $232.7M | |
| Total Debt | $671.2M | $51.4M | $41.1M | $40.8M | $33.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$150.2M | -$11.5M | $243.7M | -$5.2M | -$6.5M | |
| Cash From Investing | $7.1M | -$4.1M | -$90.2M | -$17.4M | -$100.2M | |
| Cash From Financing | -$203.8M | -$32.7M | -$2.1M | -$372K | -$400K | |
| Free Cash Flow | -$152.3M | -$12.3M | $243.5M | -$5.2M | -$6.5M | |
TBPH
Sector
Market Cap
$947.6M
$28.4M
Price % of 52-Week High
91.98%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
0.29%
-1.32%
1-Year Price Total Return
95%
-22.19%
Beta (5-Year)
0.143
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$19.17
200-day SMA
Buy
Level
$12.02
Bollinger Bands (100)
Buy
Level
12 - 16.56
Chaikin Money Flow
Buy
Level
1.2M
20-day SMA
Buy
Level
$18.01
Relative Strength Index (RSI14)
Buy
Level
59.08
ADX Line
Buy
Level
47.72
Williams %R
Neutral
Level
-46.4387
50-day SMA
Buy
Level
$15.78
MACD (12, 26)
Buy
Level
1.05
25-day Aroon Oscillator
Buy
Level
76
On Balance Volume
Neutral
Level
23.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.0295)
Sell
CA Score
(Annual)
Level (-0.7892)
Sell
Beneish M-Score
(Annual)
Level (-0.7818)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (1.3518)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.
Stock Forecast FAQ
In the current month, TBPH has received 5 Buy ratings 2 Hold ratings, and 0 Sell ratings. The TBPH average analyst price target in the past 3 months is $26.71.
-
Where Will Theravance Biopharma, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Theravance Biopharma, Inc. share price will rise to $26.71 per share over the next 12 months.
-
What Do Analysts Say About Theravance Biopharma, Inc.?
Analysts are divided on their view about Theravance Biopharma, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Theravance Biopharma, Inc. is a Sell and believe this share price will drop from its current level to $13.00.
-
What Is Theravance Biopharma, Inc.'s Price Target?
The price target for Theravance Biopharma, Inc. over the next 1-year time period is forecast to be $26.71 according to 7 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is TBPH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Theravance Biopharma, Inc. is a Buy. 5 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of TBPH?
You can purchase shares of Theravance Biopharma, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Theravance Biopharma, Inc. shares.
-
What Is The Theravance Biopharma, Inc. Share Price Today?
Theravance Biopharma, Inc. was last trading at $18.71 per share. This represents the most recent stock quote for Theravance Biopharma, Inc.. Yesterday, Theravance Biopharma, Inc. closed at $18.70 per share.
-
How To Buy Theravance Biopharma, Inc. Stock Online?
In order to purchase Theravance Biopharma, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get TBPH Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
TBPH
Sector
P/E ratio
33.24x
23.66x
PEG ratio
-0.26x
-0.01x
P/B ratio
4.07x
1.84x
Price / LTM sales
11.74x
1.60x
Growth Metrics
TBPH
Sector
Revenue growth
18.51%
4.85%
Earnings growth
126.88%
11.15%
Revenue (5-year growth)
-2.59%
6.45%
Earnings forecast
-$0.05
-$0.20
Profitability
TBPH
Sector
Profitability FY 2024
$58.4M
$3.6M
Return on invested capital
11.74%
-30.98%
Return on assets
7.74%
-27.62%
Return on equity
14.9%
-36.69%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
9
Balance Sheet
TBPH
Sector
Total cash
$329.7M
$27.2M
Short term investments
$50.6M
$25.7M
Total assets
$354.2M
$79.9M
Long term debt
$33.7M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 18.9% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
